New combo therapy aims to tackle tough prostate cancer

NCT ID NCT06499870

Recruiting now Disease control Sponsor: Sean Sachdev Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether adding two hormone-blocking drugs, relugolix and enzalutamide, to standard radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if it lowers the chance of cancer returning after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relugolix and enzalutamide (hormone therapy drugs) plus radiation therapy
What this could lead to: If successful, this combination could offer a more effective treatment option for men with very-high-risk prostate cancer, potentially reducing recurrence and improving survival.
What could go wrong: This is an early phase II trial with only 50 participants, so results may not apply to everyone. Hormone therapy can cause side effects like hot flashes, fatigue, and sexual dysfunction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.